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ABSTRACT
SpylA is an essential cell cycle protein, functioning similar to a cyclin, activating the
cyclin dependent kinase (CDK) family and enhancing cell growth processes This body of
research confirms that SpylA protein is tightly regulated during mammary gland development
Utilization of a munne mammary fat pad transplant model demonstrates that ectopic SpylA
expression increases the rate of cell proliferation, leading to precocious mammary gland
development and acceleration of breast cell tumongenesis Additionally. SpylA protein was
present in the invasive breast cancer cell line, MDA-MB-231 and in human female brain cancers
metastasized from pnmary breast tumors. It was also shown that SpylA interacts with Axin,
elucidating a potential role of SpylA in the Wnt signaling pathway Knowledge provided from
this research contnbutes to a more comprehensive understanding of cellular mechanisms
underlying the development and progression of breast cancer, highlighting SpylA as a potential
biomarker for diagnosis of invasive breast cancers
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CHAPTER I
INTRODUCTION
The Cell Cycle
Eukaryotic cellular development depends on precise and tightly regulated
succession through the cell cycle. This highly sophisticated process can be divided into
two general phases; a growth and preparation interphase followed by a divisional phase
of mitosis (M). Interphase is subdivided into three phases, which include Gap 1 (Gi),
Synthesis (S) and Gap 2 (G2) (Vermeulen et al. 2003). During the first stage of the cell
cycle, Gi, a cell begins its preparation for synthesis by undergoing an increase in cell size
and cytosolic volume, accompanied by replication of its organelles (Norbury & Nurse
1992). At this stage a cell can exit the cell cycle to enter a stationary phase called Go,
where it retains the ability to re-enter the cell cycle if exposed to the appropriate stimuli
and favorable growth conditions. A cell can then progress from either Gi or Go phase into
S phase of the cell cycle, where its DNA is replicated before it passes into G2, its second
and final preparation phase. This stage is important for monitoring the integrity of the
replicated DNA, ensuring that any damages are mended before division, as well as
serving as the time for activation of necessary mitotic proteins (Pardee 1989). The cell
finally progresses into the last phase of the cell cycle, M phase, where it undergoes
nuclear division and cytokinesis to become two daughter cells, each of which contain
identical genetic information to their parental cell (Pardee 1989).
Cell Cycle Regulation
The intricate progression of a cell through its cell cycle is dictated by various
regulatory mechanisms, all of which exist to ensure the integrity of the cell material is
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preserved during replication. These mechanisms are mainly governed by a family of
kinases referred to as the cyclin dependent kinases (CDK) and their regulatory binding
partners, the cyclins. CDKs are largely responsible for the regulation of movement from
one phase of the cell cycle to the next. These serine/threonine protein kinases are
structurally similar to many other basic protein kinases; they contain an N-terminus rich
in p-sheets and a large C-terminus mostly consisting of a-helices, with an active site for
ATP binding and catalysis embedded within the center region of the protein (Pavletich
1999). In order to become an active kinase, a CDK must first bind to its specific
regulatory subunit cyclin (Ekholm & Reed 2000). These cyclin proteins contain a cyclin
box, a highly conserved region of 100 amino acids, which allows for direct binding with
its CDK partner (Murray 2004). In contrast to CDKs, which are present at consistently
high levels, cyclin availability is tightly controlled during the stages of the cell cycle
through transcriptional up-regulation as well as proteolysis via ubiquitin-mediated
degradation (Morgan 1995). Cyclin binding causes the T-loop of the CDK to undergo
conformational change, revealing the CDK's active site, which is then phosphorylated by
cyclin activating kinase (CAK) on a critical threonine residue (Thrl60 or Thrl61 of
CDK2 and CDK1, respectively) (Russo et al. 1996). The full activity of the CDK-cyclin
complex is then achieved by dephosphorylation by CDC25 phosphatases on threonine
and tyrosine residues (Thrl4 and Tyrl5 in CDK1 and CDK2) (Dunphy 1994). The active
CDK-cyclin complex then has the ability to phosphorylate downstream target proteins
required for proper progression and cell division (Morgan 1995).
The activities of CDKs are subject to inhibition via two classes of CDK inhibitors
(CKI), the Cip/Kip family and the INK4 family, which provide a strong method of cell

2

cycle regulation. The Cip/Kip family includes proteins p21 Wa

Cipl

, p27

p

, and p57

p

(Sherr & Roberts 1999). These inhibitors mainly exhibit their effects during Gi phase,
where they act directly on CDK-cyclin complexes, namely CDK.4/6 and their Cyclin D
(Dl, D2, D3) partners, but can also act on CDK2-CyclinA/E during the Gi/S transition
and S phase, respectively, as well as CDKl-Cyclin B during M phase (Harper et al. 1995;
Hengst & Reed 1998; Lee et al. 1995; Polyak et al. 1994). Examples of Cip/Kip
inhibitory activity include p21, which is transcriptionally upregulated in response to
activation of the tumor suppressor protein p53, due to strong response elements for p53 in
its promoter region. Up-regulation of p21 in response to p53 activation results in an
abundance of p21 protein, which can then bind to and inhibit CDK2, arresting a cell in Gi
(Harper et al. 1993).
All Cip/Kip inhibitors are not exclusively under transcriptional control, and can
also be regulated translationally, as in the case of p27 Unlike p21, transcription of the
p27 gene is constitutive, but its regulation mainly occurs through translation (Hengst &
Reed 1996). Levels of p27 protein are typically high during Gi and Go phases. For
successful transition between Gi and S phase, normal phosphorylative activity of the
CDK2-cycle E complex is necessary for synthesis of DNA, but p27 can bind to and
inhibit CDK2-Cyclin E, preventing any early S phase entry (Nakayama et al. 2001).
Interestingly, it is also known that p27 can inadvertently speed up Gi/S transition because
it can bind to CDK4-Cyclin D, which then decreases the amount of p27 available to bind
and inhibit CDK2-Cyclin E. To add further intricacy to the interactions, p27 is a protein
target of CDK2-Cyclin E phosphorylation. This is evidence of translational regulation of
p27, since phosphorylation targets it for ubiquitination by SCF (Skpl-Cullin-1-F-box)
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family of protein ligases, degrading p27 via proteolysis. The combined effects of CDK2Cyclin E activity and its consequential p27 proteolysis aid in the Gi/S transition (Carrano
et al. 1999; Montagnoli et al. 1999; Nguyen et al. 1999).
The second family of CKIs, the INK4 family, includes proteins pl51N1C4b, pl6 INK4a ,
pig1™40, and pl9INK4d (Sherr & Roberts 1999). These inhibitors differ from the Cip/Kip
family in that they bind directly to the non-catalytic side of the CDK, preventing binding
to its cyclin activating partner (Russo et al. 1998). INK4 inhibitors are specific to CDK.4
and CDK6, which help to regulate the transitions between Gi/S and G2/M (Caraero &
Hannon 1998).
CDK-cyclin complexes can also be inactivated by phosphorylation of the same
threonine and tyrosine residues (Thrl4 and Tyrl5) on the CDK that is required to be
dephosphorylated for CDK activation. This reversal of dephosphorylation is very
important after the G2/M and M complexes of CDK1-Cyclin A and CDK1-Cyclin B have
phosphorylated downstream targets, such as histones and structural proteins required for
cytokinesis, which are necessary for initial entry into M phase and successful completion
of the cell cycle. Phosphorylation of Thrl4 and Tyrl5 is carried out by the Weel and
Mytl kinases, causing dissociation of the cyclin from its CDK partner (Lew & Kornbluth
1996). Shortly after this phosphorylation, the cyclin is degraded via the anaphase
promoting (APC) complex, which aids in the completion of the cell cycle (Coleman &
Dunphy 1994).
The cell cycle is clearly a diverse interaction of factors, working cohesively in
order to lead a cell to proper division. Recently, it has been shown that a family of
proteins named Spyl/RINGO, can perform as atypical cyclins, binding and activating

4

CDKl and CDK2 (Nebreda 2006). This discovery has revealed a deeper layer of
complexity to regulation and warrants the investigation of the Speedy/RINGO family to
fully elucidate their roles in the cell cycle.
Discovery ofXenopus Speedy (X-Spyl)
Speedy (Spyl) was first discovered as a novel gene product in Xenopus (X-Spyl)
by two separate laboratories independently and practically simultaneously in the late
1990s. The first published identification came from the Donoghue Lab, where X-Spyl
was revealed through a genetic screening of a Xenopus ovary cDNA library, used to
determine novel genes that could be important during the G2/M transition of the cell
cycle.

They carried out this screen in a Radl deficient strain of fission yeast.

Schizosaccharomyces pombe (Lenormand et al. 1999). Without Radl, a cell cycle gene
which is required for arresting cells at the G2/M checkpoint at the onset of any DNA
damage or incomplete DNA replication, cells that encounter damaging agents
consequently undergo cell death due to their failure to arrest in Gi/M (al-Khodairy &
Carr 1992; Hartwell & Weinert 1989). This genetic screen showed that expression of the
X-Spyl clone could override sensitivity to UV or gamma radiation, allowing the cells to
overcome G2/M arrest. These results indicated X-Spyl "s potential role as a cell cycle
regulator (Lenormand et al. 1999).
Shortly after this initial X-Spyl report, the Nebreda Lab published the
independent isolation of a novel protein, which they identified as X-RINGO (Rapid
INducer of G2/M progression in Oocytes) (Ferby et al. 1999). A screen utilizing an
expression cloning strategy for any genes significant in the G2/M transition of Xenopus
oocytes pulled out two isoforms of X-RINGO protein. One of these isoforms is 99%
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homologous to X-Spyl, and for purpose of this thesis will be referred to as X-Spyl
(Porter et al. 2002).
Its involvement in the G2/M transition led investigators to study the role of XSpyl in Xenopus oocyte meiosis more closely. Once a vertebrate oocyte completes its
growth, it naturally arrests at prophase in meiosis I phase until stimulated by a maturation
inducing hormone (MIH) (Bhattacharya et al. 2007). In the case of all vertebrates except
for fish, the MIH is a steroid hormone, progesterone. MIH expression promotes the
formation of the maturation promoting factor (MPF), which is a CDKl-Cyclin B
complex that results in the final marker for oocyte maturation, germinal vesicle break
down (GVBD) (Bhattacharya et al. 2007).
Overexpression of X-Spyl in Xenopus oocytes arrested in the G? phase of
meiosis, increases the rate of meiotic maturation at a faster rate than induction of
progesterone (Ferby et al. 1999; Lenormand et al. 1999). In the absence of progesterone,
both overexpression of X-Spyl mRNA or X-Spyl protein induces GVBD and MPF
activation. Consequently, knockdown of X-Spyl using antisense oligonucleotides delays
oocyte maturation when treated with progesterone (Ferby et al. 1999). This research
demonstrates that X-Spyl is required for normal oocyte maturation.
Speedy/RINGO Family
Since the discovery of X-Spyl, potential Speedy genes have been identified in
even the most ancient clade of chordates, Ciona intestinalis. although Speedy
homologues have only been found in a subset of invertebrates. The discovery and study
of these vertebrate Spyl proteins have governed classification of a novel protein family,
the Speedy/RINGO family (Cheng et al. 2005b). Generally, these proteins have been
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shown to bind and activate CDKs, although they have no homology to typical cyclin
proteins. In addition to their requirement and enhancement of Xenopus oocyte
maturation, they are also known to have roles in cell proliferation, checkpoint regulation
and apoptosis (Gastwirt et al. 2007).
To date, there are five known mammalian Speedy homologues, which include
Speedy Al, Speedy A2, and Speedy B through E. These proteins are expressed in
specific tissues and have different binding preferences for CDKs. Speedy Al and A2 are
thought to be splice variants, and have both been found in Homo sapiens and Mus
musculus. Speedy Al binds to CDK2, whereas Speedy A2 can bind both CDK1 and
CDK2. Both isoforms are expressed in many tissues, but specifically at high levels in the
testis (Cheng et al. 2005b; Dinarina et al. 2005; Kume et al. 2007; Porter et al. 2002).
Speedy B has been found in the testis of Mus musculus and binds to CDK1. Speedy C has
also been found in Homo sapiens, has a binding preference for both CDK1 and CDK2,
and is present in testis as well as in the liver, kidney, placenta, bone marrow and small
intestine. Speedy D, found in Mus musculus, has unknown tissue expression and CDK
preference, whereas Speedy E, found in Homo sapiens, has unknown tissue expression
and can not only bind to CDK1 and CDK2, but has also been shown to bind CDK5
(Cheng et al. 2005b; Dinarina et al. 2005).
Each of the Speedy proteins has a central region, distinguished as the
Speedy/RINGO box. This highly conserved sequence is approximately 100 amino acids
and is 51-67% identical among the Speedy/RINGO family of proteins. This region is
important for CDK binding and mutations in this region abrogate the ability of
mammalian Spy protein to bind CDKs and X-Spy to induce GVBD (Cheng et al. 2005b;
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Dinarina et al. 2005). The termini of Speedy/RINGO family members vary in length and
share sparse sequence identity. Mutations within the C-terminus of SpylA2 can bind
CDK2, but cannot activate it, demonstrating that the C-terminus is important for the
promotion of CDK activation. It is proposed that the N-terminus could influence the
regulation of Speedy protein expression (Cheng et al. 2005b). Lack of homology in the
terminal regions may indicate specific functional roles of the various Speedy family
members with regards to their expression and activation of CDKs (Gastwirt et al. 2007).
It has also been demonstrated that CDK-Spyl complexes have preference towards
different substrates compared with typical CDK2-Cyclin complexes. CDK2-SpylA2
demonstrates decreased enzymatic activity towards CDK2-cyclin substrates with
(S/T)PX(K/R) consensus site. Specifically, CDK2-SpylA2 has almost 1000-fold and 10fold decrease in activity towards Histone HI and CDC25 phosphatases, respectively
(Cheng et al. 2005a). It was shown that CDK is a poor substrate for CAK, such that when
bound to Spyl, the CDK does not require phosphorylation by CAK for activation (Cheng
et al. 2005a). Mytl shows decrease in phosphorylation of XRINGO/CDK in comparison
to CDKl-Cyclin B (Karaiskou et al. 2001). Additionally. CDK2-SpylA2 complex
phosphorylates noncanonical sites atypical of CDK2-Cyclin A, which could provide
further evidence for Spyl proteins phosphorylating substrates with unique or
undiscovered roles within the cell cycle, such as checkpoint control or apoptosis (Cheng
et al. 2005a).
This thesis is focused on the study of the first discovered human Speedy
homologue, Spyl Al, hereafter referred to as Spyl A, which was found through a database
search of a testis cDNA library. As briefly eluted to above, this expression sequence tag
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(EST) clone had 63% homology over a 170 base pair (bp) region of X-Spyl. SpylA was
then isolated from a testis cDNA library and cloned through a serial dilution PCR
method. This clone encoded a predicted 286 amino acid polypeptide, which is 40%
homologous to X-Spyl and notably shares a 150 amino acid region with 70% homology
(Porter et al. 2002). The sequence homology between X-Spyl and SpylA led
investigators to study its functionality, both in vitro and in vivo. Injection of SpylA
mRNA into Xenopus oocytes in the absence of progesterone also induces maturation,
although not as effectively as X-Spyl (Porter et al. 2002).
Role of SpylA in the Mitotic Cell Cycle
While the importance of X-Spyl in meiosis was established, the fact that the
SpylA isoform was detected at high levels in tissues devoid of germ cells such as the
human fetal brain, the thyroid gland, the liver, the heart, and the placenta, led to the study
of mammalian SpylA in cell cycle progression (Porter et al. 2002). When investigating
the link between SpylA and cell cycle regulation it was found that endogenous SpylA
mRNA was present only at the Gi/S transition. As well, immunofluorescence of cells
over-expressing SpylA showed its localization to the nucleus, although recent
unpublished data demonstrates that SpylA is shuttled to the cytoplasm in a regulated
fashion. SpylA also interacts with CDK2 and stimulates its kinase activity,
independently of any binding to cyclin protein (Porter et al. 2002). Spyl has also been
shown to bind CDK2 T160A mutants just as effectively as wild-type CDK2, indicating
that SpylA does not require phosphorylation of Thr-160 in the activation loop of the
kinase domain for binding or activation of CDK2 (Karaiskou et al. 2001).
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SpylA overexpression increases the rate of DNA replication, increasing BrdU
incorporation three-fold compared to mock cells and increasing mitochondrial activity,
determined via MTT assay (Porter et al. 2002). Importantly, flow cytometry experiments
demonstrate that SpylA overexpression reduces the population of cells in Gi phase of the
cell cycle compared to mock cells. It was determined that SpylA mediated effects on
increased cell proliferation are dependent on the kinase activity of CDK2.

Upon

inhibition of CDK2 kinase activity through a dominant-negative CDK2 and olomoucine,
a drug shown to inhibit CDK2 activity, overexpression of SpylA can no longer stimulate
proliferation (Porter et al. 2002). Treatment of 293T cells with small interfering RNA
(siRNA) against SpylA diminishes endogenous levels of SpylA in the cells,
consequently causing negative cell proliferation effects. Absence of SpylA results in a
lower mitotic index of cells and lower level of CDK2 associated histone HI kinase
activity, along with a higher population of cells in late Gl/early S phase (Porter et al.
2002). Collectively, these results demonstrate the essentiality of SpylA in cell cycle
progression.
In addition to its direct interaction with CDK2, a yeast two-hybrid screen showed
p27 to be a potential interacting partner for SpylA. As previously stated, p27 typically
interacts with and inhibits CDK2-Cyclin E by binding to the conserved RXL motif of the
cyclin and inserting its C-terminus into the CDK's ATP binding pocket, consequently
preventing early entry into S phase (Nakayama et al. 2001). Both in vitro and in vivo
studies have confirmed that SpylA is a binding partner of p27, where SpylA binds to the
CDK-binding region but not the cyclin-binding region of p27. In mammalian cells,
overexpression of SpylA is capable of overcoming a p27-induced Gi cell cycle arrest,
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demonstrating degradation of p27, resulting in an increase in CDK2 kinase activity and
DNA synthesis (Porter et al. 2003). SpylA can form a trimeric complex with p27 and
CDK2, where increasing levels of p27 in turn increase SpylA association with p27CDK2. Additionally, CDK2-SpylA binding is increased in the presence of p27 (Porter et
al. 2003). It is also interesting to note that in p27 null cell lines, SpylA can still bind to
CDK2, but proliferation rates of these cells are equivalent to SpylA over-expressing p27
null cells. Demonstrating that the CDK2-SpylA interaction may have functional
significance independent of p27, however this supports the hypothesis that the ability of
SpylA to increase cell cycle progression at the Gj/S transition may be mediated through
direct interactions with p27 (Porter et al. 2003).
Role of SpylA in the DNA Damage Response andApoptosis
To ensure proper division, checkpoints exist at the Gj/S and G2/M transitions of
the cell cycle to ensure inhibition of progression in the event a cell encounters DNA
damage, until the DNA is repaired, or in some cases, the cell is signaled for cell death
(Gastwirt et al. 2007). CDK activity is vitally important during the DNA damage
response, leading investigators to logically hypothesize that SpylA could also be
involved.
During the DNA damage response, CDK activity is typically controlled by
destruction of CDC25 phosphatases via Chkl/Chk2 induced phosphorylation (Xiao et al.
2003). CDC25 proteins, as previously mentioned, function to dephosphorylate CDKcyclin complexes to enable their full activation (Dunphy 1994). Without the CDC25
phosphatase activity, CDKs cannot act on downstream targets, thereby halting cell cycle
progression. Another method of CDK inhibition in response to DNA damage is the p53
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induced activation of the CKI p21 (Ogryzko et al. 1997). It is also important to note that
while CDK activity is generally inhibited dunng the DNA damage response, its inhibition
of activity can be detnmental to DNA damage repair, particularly with regard to repair of
double strand breaks. Therefore, small amounts of positi\ e CDK2 regulation dunng the
DNA damage response may be beneficial to the cell sun i\ al (Deans et al. 2006).
To determine the potential role of SpylA in the DNA damage response,
mammalian cells were exposed to vanous genotoxic DNA damaging vehicles, such as
cisplatin and hydroxyurea. Such treatment was shown to increase endogenous SpylA
protein levels. Overexpression of SpylA protein increases cell sunhal following
treatment with genotoxic agents. When siRNA is utilized to knock down SpylA, the
increased survival rate is eliminated and apoptosis increases (Barnes et al. 2003). It has
also been shown that SpylA overexpression increases the long term viability of cells
treated with camptothecin (CPT), a topoisomerase inhibitor (Barnes et al. 2003). To
further investigate the increased viability, DNA fragments were measured \ia comet
assay following CPT treatment, demonstrating that overexpression of SpylA decreases
DNA fragmentation. This could indicate either a decrease in DNA damage or a decrease
in apoptotic cells (Barnes et al. 2003). It is also known that these effects are dependent on
SpylA's interaction with CDK2 to form an active complex Generally, SpylA is acting
in a similar fashion to other checkpoint proteins such as p53 and p21. which expenence
increased levels in response to DNA damage. This indicates that CDK2/Spyl A can play a
role in DNA damage repair (Gastwirt et al. 2006). With regards to apoptotic effects,
mammalian cells were treated with UV-radiation. Expenments revealed that SpylA
overexpression inhibits apoptosis through direct inhibition of pro-apoptotic pathways. It
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also allows for UV-radiation resistant DNA synthesis as well as progression into M
phase. This indicates that SpylA plays a role in both Gl/S and G2/M checkpoints of the
cell cycle in response to DNA damage (Gastwirt et al. 2006).
SpylA could be exhibiting its effects on the DNA damage response and apoptosis
through several different mechanisms. Since it has been shown that CDK2/SpylA has
different substrate preference in comparison to typical CDK/cyclin complexes, it is
possible that CDK2/SpylA complexes have the ability to phosphorylate substrates that
are unique to the DNA damage response, without influencing the activity of typical
CDK/cyclin substrates (Gastwirt et al. 2007). It is also feasible that SpylA, with the
potential to activate CDC25 phosphatase family members, can cause a positive feedback
loop, leading to a population of constitutively active CDK2 (Cheng et al. 2005a; Solomon
et al. 1990). As well, since CDK2/SpylA has been shown to be resistant to inhibition by
p21, this itself could create a population of active CDK2 during checkpoints where it is
typically inhibited (Gastwirt et al. 2007; Karaiskou et al. 2001).
The unique role of Spyl/CDK2 in the DNA damage response and apoptosis is not
yet fully elucidated, however, experimental evidence leads to the possibility that
inappropriate regulation of this protein could lead to genomic instability and therefore,
potentially have oncogenic implications. Search of the NIH/NCI SAGE database shows
that Spyl is present in high levels in colon and pancreatic cancers (Gastwirt et al. 2007).
Most important to this body of work, it has also been revealed through SAGE analysis
that Spyl is one of the fifty most upregulated genes in invasive breast ductal carcinoma
(Zucchi et al. 2004).
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Mammary Gland Development
The work within this thesis is focused on understanding the role of SpylA in
mammary tumorigenesis. In order to study oncogenic events in the mammary gland, it is
first necessary to understand normal mechanisms of its development. The developing
mammary gland is a very useful system for the study of cell regulation. The majority of
its growth and development occurs after birth when the mammary fat pad is filled by
swift extension of a network of epithelial cells, allowing for post-embryonic
investigation. As well, cell cycle regulators can be studied as the developing gland
undergoes proliferation, differentiation, and apoptosis during stages of pregnancy,
lactation, and involution, respectively (Andrechek et al. 2008).
Perhaps most beneficial to researchers is the fact that the mammary gland is not a
vital organ to the survival of its organism, which allows for its manipulation during in
vivo study. Development of mouse mammary glands begins around embryonic day 11
with the formation of five mammary placodes, which slightly extend beyond the body
wall (Robinson 2004). These placodes form along two milk lines and by embryonic day
12, the placodes form bulb shaped epithelial buds. These epithelial buds then grow and
invade into the mammary fat pad by embryonic day 15.5. Primary sprouts appear from
these buds, each forming a lumen that connects to the surface of the skin through the
nipple. By embryonic day 16 the sprouts begin to branch, continuing expansion into the
glands by embryonic day 18.5 (Veltmaat et al. 2003).
Terminal end buds (TEBs) are structures located at the distal end of the epithelial
branches and they direct elongation and subsequent creation of the ductal network within
the mammary fat pad (Andrechek et al. 2008; Ball 1998). TEBs first appear in the gland
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between late gestation and one week of age in response to maternal hormones, but as
these hormones decrease, the size and number of TEBs begin to decrease
correspondingly. As the animal continues to grow, the mammary gland grows
proportionally with the body and TEBs temporarily become mitotically quiescent
structures called terminal end ducts (TEDs) (Ball 1998; Williams & Daniel 1983).
Reproductive hormonal stimulation of the pubescent mammary gland at approximately 4
weeks of age, reinstates the actively mitotic TEBs, and ductal morphogenesis continues
(Sekhri et al. 1967; Williams & Daniel 1983). Once the ductal network reaches the
limitations of the mammary fat pad, TEBs become replaced with permanent TEDs
(Andrechek et al. 2008; Ball 1998; Williams & Daniel 1983). Structurally, TEBs are
composed of an outer layer of undifferentiated, pleuripotent cells. These stem-like "cap
cells' have been shown to give rise to luminal and myoepithelial cells of the developing
mammary ducts. Since these cap cells have a shorter Gi phase, they could be more
vulnerable to genetic mutation, marking the developing pubescent mammary gland as a
crucial time for potential carcinogenesis (Williams & Daniel 1983). Further, it has been
shown that when carcinogens are introduced to an early stage developing mammary
gland, the undifferentiated cap cells in the TEBs undergo significant mutations (Russo &
Russo 1987).
Upon successful pubertal development, when a mouse becomes pregnant, the
mammary gland undergoes another series of rapid proliferation and epithelial branching.
Once the mouse has given birth, the gland is filled with alveoli, which allows for milk
secretion. Approximately 21 days post-birth, pups are weaned from the mother, inducing
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a stage of involution in the mammary gland, characterized by apoptosis and resulting in a
phenotypically similar gland to that of a virgin mouse (Andrechek et al. 2008).
Molecular Regulations during Mammary Gland Development and Tumorigenesis
The development of the mammary gland, which as detailed above broadly
encompasses stages of growth, cell proliferation, differentiation, and apoptosis, occurs
rapidly within a short span of time. To ensure normal development, an intricate system of
hormonal and signaling mechanisms must be tightly regulated, where any altercation
could potentially result in aberrant development. During maturity of the mammary gland
the epithelial buds are surrounded by concentric layers of mesenchymal cells, which form
the stroma of the adult gland. It is the molecular regulation via epithelial-mesenchymal
signaling that controls proper mammary gland development (Hennighausen & Robinson
2001; Robinson 2004).
Commencement of puberty stimulates ductal outgrowth, mainly controlled by
signaling of epidermal growth factor (EGF) and fibroblast growth factor 10 (FGF10),
which help to regulate rapid proliferation (Mailleux et al. 2002; Medina 1996). Hormones
are also active during this time, and although estrogen is not required for mammary gland
development before puberty, at puberty's onset estrogen promotes rapid cell proliferation
(Hovey et al. 2002). Additionally, estrogen and progesterone can aid in ductal elongation
and lateral branching (Silberstein et al. 1994). Estrogen also regulates c-Myc, a
transcription factor downstream of MAPK signaling. C-Myc levels are also low during
pregnancy and considerably increased upon lactation and through early involution
(Andrechek et al. 2008). Overexpression of c-Myc during pregnancy also results in
precocious lactation (Blakely et al. 2005). With relation to SpylA, evidence exists to
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implicate it is downstream of c-Myc, which could also associate estrogen as an upstream
effector of SpylA (Golipour et al. 2008).
Pregnancy, which is characterized by cellular differentiation in preparation for
lactation, is also hormonally regulated. Prolactin, a pituitary peptide hormone, is a main
signaling factor for the regulation of growth and differentiation of epithelial cells during
pregnancy (Traurig 1967). Binding of prolactin to its prolactin receptor activates Janus
Kinase (JAK2), which leads to downstream activation of transcription activators such as
STAT (Ihle 1996; Schindler & Darnell 1995). STATs, namely, STAT5A and STAT5B.
can then enter the nucleus to promote gene expression of proteins such as the milk
protein, beta-casein (Ihle 1996; Schmitt-Ney et al. 1991). Following birth of pups,
lactation occurs through epithelial differentiation and after pups have been weaned, the
gland undergoes rapid involution (Robinson 2004; Walker et al. 1989). Similar to the cMyc expression profile, Ras, a G-protein proto-oncogene and Src, a proto-oncogene
kinase, had low levels during pregnancy with rapid increase during lactation and early
involution. Although these pathways are associated with cell proliferation, they are
clearly very tightly regulated during development of the mammary gland (Andrechek et
al. 2008).
Wnt Signaling during Mammary Gland Development and Tumorigenesis
Wnt signal transduction is yet another major pathway that influences mammary
gland development. Highly conserved through evolution and present in organisms from
nematode worms to humans, Wnt proteins play roles in the regulation of a cell's
proliferation, motility, morphology and fate and also influence axis formation and organ
development (Polakis 2000; Wodarz & Nusse 1998). Wnt proteins are cysteine-rich
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glycoproteins that can act through two different signaling pathways, canonical and noncanonical. There are now 19 classified Wnt proteins in mammals which commonly fall
into two categories. There are classical Wnts such as Wntl, Wnt3a, Wnt8, which act
through the canonical pathway and non-classical Wnts such as Wnt4, Wnt5a, Wntll,
which act through the non-canonical pathway (Widelitz 2005).
The canonical pathway of Wnt is sometimes referred to as the P-catenin pathway
(Kikuchi 2003). Generally, in the absence of Wnt signaling, p-catenin cytoplasmic levels
are low. This is because P-catenin can be bound to the cytoplasmic domain of type I
cadherins, such as E-cadherin, where it plays a role in structural organization of the actin
cytoskeleton (Takeichi 1991). But if it has excess binding sites, P-catenin is
phosphorylated by two kinases, CKIa and GSK-3P, within an Axin complex, where Axin
acts as a scaffolding protein (Jamora et al. 2003; Kikuchi 1999; Liu et al. 2002). When Pcatenin is phosphorylated, it is signaled for ubiquitination and consequently degradation
via the proteasome (Kitagawa et al. 1999). When Wnt signaling is active, Wnt binds to
the cell surface receptor, which is composed of Frizzled, a G-protein coupled receptor,
and LRP5/6 (low-density lipoprotein receptor-related protein 5/6), which are single
transmembrane receptors (Turashvili et al. 2006). This binding causes the cytoplasmic
phospoprotein, Dvl (Disheveled) to compromise the action of GSK-3P, via an unknown
mechanism. The inability of GSK-3P to phosphorylate p-catenin results in P-catenin
dissociating from the Axin complex. P-catenin is no longer degraded and as a result, its
cytoplasmic levels accumulate, where it can bind to cadherins at the plasma membrane to
increase cell-cell adhesion as well as translocate into the nucleus. Once in the nucleus, Pcatenin binds to the transcription factor Tcf/Lef to stimulate the expression of genes such
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as c-Myc and Cyclin D1, which contain Tcf/Lef binding sites in their promoters (Polakis
2000) (Hurlstone & Clevers 2002).
With respect to mammary gland development, Wnts have been implicated in
murine stages ranging from growth and development to involution (Hatsell et al. 2003;
Lacher et al. 2003). Wnt signaling component Lef is expressed in the epithelial buds at
embryonic days 11 and 12 and in the mesenchyme cells around each bud by day
embryonic 14 and 15 (Foley et al. 2001). It has also been shown by whole mount in situ
hybridization that Wnt 10b is also expressed in the mammary glands at this time
(Christiansen et al. 1995). Lef is required for proper mammary bud development, where
if the Lef gene is absent, animals develop with no mammary glands (van Genderen et al.
1994). Wnt has also been implicated as having a role in post-natal development of the
mammary gland. Several Wnt proteins and members of the Frizzled family are expressed,
some showing peaks of expression during puberty (Bergstein et al. 1995). The ectopic
expression of Wnt in the mouse mammary tumor virus {MMYW)-Wntl transgenic mice
results in faster ductal outgowth compared to controls, which leads to lobuloalveolar
hyperplasia and virgin transgenic mammary glands resemble wild-type mammary glands
in mid-pregnancy (Lane & Leder 1997; Lin et al. 1992). It is still not certain if these
effects are mediated by canonical or non-canonical Wnt signaling. Transgenic mice
expressing stable P-catenin levels, MMTV-ANfi-catenin, produce a similar phenotype to
MMTV- Wntl mice, indicating that the precocious development is due to canonical
signaling. However, the MMTV-ANfi-catenin mice do not express premature hyperbranching of the mammary ducts, as seen in MMTV-Wntl mice, further indicating that
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both canonical and non-canonical Wnt signaling may be playing a role in mammary
gland development and carcinogenesis (Imbert et al. 2001; Michaelson & Leder 2001).
In conclusion, there are many influences to mammary development, but it is still
unknown in many cases if these regulating pathways act independently of each other or if
they are interrelated (Robinson 2004). Regardless, it is important to note that erroneous
signaling within any of these regulatory mechanisms can ultimately lead to mammary
hyperplasia, resulting in mammary tumorigenesis.
Using the Mammary Gland as a Model System
While knockout and inducible mouse models are frequently utilized in the
characterization of various genes that influence oncogenic events in the mammary gland,
it remains important to study these genes at a cellular level. Epithelial cells found in the
mammary gland throughout its development have morphological characteristics crucial to
their cellular function, including cell-cell contacts which are involved in signaling,
polarized morphology essential for proper structure during growth and an attachment to
the basement membrane. Interruption in normal mammary epithelia can lead to mammary
epithelial tumor formation (Fauquette et al. 1997).
Tissue culture use of mammary epithelial cells has allowed researchers to closely
study various factors that influence the characteristics of mammary epithelial cells. In
particular, a mammary epithelial cell line derived from a mid-pregnant BALB/c mouse.
HC11, has been frequently used to study cellular growth, differentiation and migration
(Baratta et al. 2000; Fini et al. 2008; Marte et al. 1995). These cells are immortalized and
non-transformed, and display spherical formation in culture, similar to mammosphere and
acini formation in primary mammary epithelial cells and mammary gland in vivo,
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respectively (Humphreys & Rosen 1997). The HCll cell line can also be used in the
cleared fat pad transplant technique, utilizing BALB/c mice. This technique involves the
clearing of the prepubescent fourth inguinal mammary gland from the TEBs, where
HC11 cells can then be injected into the cleared fat pad, reestablishing the mature gland
(Brandt et al. 2001). By utilizing HC11 cells stably expressing a gene of interest, such as
SpylA, the fat pad transplant acts as a reliable method to study the effects of ectopic gene
expression on mammary growth, development, and carcinogenesis (Humphreys & Rosen
1997).
Metastasis and Invasion
Aberrant growth begins with uncontrolled proliferation, initiated by a complex
and highly variant sequence of events, where its progression is dependent on the
combined effects of multiple genetic lesions. In humans, primary tumors found in the
mammary glands of the breast can be removed without compromising a patients'
lifespan. However, these tumors have a high incidence of metastasizing to vital organs
and tissues, posing a life-threatening risk. The process of metastasis generally follows a
series of complicated steps, sometimes referred to as the invasion-metastasis cascade
(Weinberg 2006). This cascade is composed of very specific stages, all highly regulated
by epithelial-mesenchymal signaling. In brief, once a primary tumor has formed, in order
to metastasize it must experience localized invasion, which allows for the epithelial cells
to break through the basement membrane and into the surrounding stroma. The stroma
allows the cell close contact with nutrients and oxygen from surrounding capillaries.
From this stage, it now has the ability to intravasate into other vessels through
interactions with platelets, lymphocytes or other components of blood. The cell is then
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transported through the body via circulation, where it can stop and become arrested in a
number of tissues and organs. It must then infiltrate the surrounding tissue in order to
enter its new environment, a process termed extravasation. Here, once exposed to stimuli
from surrounding cells, the tumor cell may begin to proliferate, changing from small
micrometastases to a visibly larger macrometastases. The ability to multiply from
micrometastases to a macrometastases is called colonization. This is the rate limiting step
of metastasis, since the stimuli provided from the foreign cell microenvironment may not
supply the same growth signals as its original environment (Fidler 2003; Weinberg
2006). Many mechanisms of metastasis and invasion are still poorly understood.
Identification of key effectors of these processes may lead to a more comprehensive
knowledge of the progression of breast cancer.
Hypothesis and Objectives
The current research was designed to investigate the proposal that SpylA, an
atypical cell cycle regulator, plays a pivotal role in the development and progression of
breast cancer. Experimental aims included confirmation of endogenous SpylA protein
levels throughout a mouse mammary gland developmental time course as well as the
utilization of an in vivo mammary fat pad transplant system, using HC11 cells stably
overexpressing SpylA to examine SpylA's role in mammary gland proliferation and
tumorigenesis. The project also focused on examining the role of SpylA in migration and
invasion. Endogenous SpylA protein levels were investigated in various cancerous and
non-cancerous cell lines as well as human metastatic breast tissue to the brain.
Additionally, various cell lines were used to explore SpylA's influence on migration and
invasion through functional assays including wound healing and migration and invasion
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assays. SpylA's potential involvement in the Wnt signaling pathway through its
interaction with Axin was also investigated. Knowledge provided from this research
contributes to a more comprehensive understanding of the cellular mechanisms
underlying the complex process of breast cancer development and progression,
potentially revealing Spyl as a biomarker for diagnosis of invasive breast cancers.
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CHAPTER II
DESIGN AND METHODOLOGY
Cell Culture
MCF-10A, non-tumorigenie human breast epithelial cell line (kindly provided by
Dr. T. Seagroves, University of Tennessee), were cultured in Dulbecco*s Modified
Eagle's Medium/Nutrient F-12 Ham (Sigma), supplemented with 5% horse serum
(Sigma), 10 ug/mL hydrocortinsone (Sigma), 10 ugmL insulin (Sigma) and 20 ng/mL
epidermal growth factor (Calbiochem). HEK293. human embryonic kidney epithelial cell
line (ATCC), MDA-MB-231 and MDA-MB-468, human mammary adenocarcinoma
epithelial cell lines (kindly provided by Dr. C. Zahnow. Johns Hopkins), were cultured in
Dulbecco's Modified Eagle's Medium (Sigma), supplemented with 10% (vol/vol) fetal
bovine serum (Sigma). MCF7, human mammary adenocarcinoma epithelial cell line
(kindly provided by Dr. T. Seagroves, University of Tennessee) and HC11. BALB/C
mouse mammary epithelial cell line (kindly provided by Dr. C. Shermanko, University of
Calgary), were cultured in RPMI-1640 medium (Sigma), supplemented with 10%
(vol/vol) newborn calf serum (Sigma). HC11 growth media was further provided with 10
ng/mL epidermal growth factor (Invitrogen) and 5 ug/mL insulin (Sigma). All growth
media also contained 2 mmol/L L-glutamine (Sigma), penicillin (Invitrogen), and
streptomycin (Invitrogen). Cells were maintained at 37°C in a 5% C0 2 environment.
Plasmids and Antibodies
The pLXSN and pLXSN-Flag-SpylA constructs were previously described
(Porter et al. 2003). The pCS3-Myc and pCS3-Myc-Spyl constructs were previously
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described (Porter et al. 2002). The pCS2+-Flag-Axin construct was kindly donated by Dr.
J. Woodgett and previously described (Liu et al. 2002).
SpylA

siRNA

was

synethesized

by

inserting

the

oligo

(A078)

5'

GATCCCCGCTATGACCTTTGTTTATTTTCAAGAGAAATAAACAAAGGTCATAG
CTTTTTA into the pSUPER-basic vector according to the manufacturers protocol
(OligoEngine) by Catherine Cheng. As a control, LacZ siRNA (siCntl) was synthesized
by

the

insertion

of

the

oligo

(A3 00)

5'

GATCCCCACCCTGGCCCTGCCCAACCTGTTCAAGAGACAGGTTGGGCAGGGC
CAGGGTTTTTTA into the pSUPER-basic vector by Mohammad Al Sorkhy.
Antibodies used included human SpylA antibody, which was generated and
described previously (Porter et al. 2002), Actin (MAB1501R; Chemicon), Myc (9E10;
Santa Cruz), PCNA (93-1143; Zymed), IgG (SC66186; Santa Cruz), and Flag (F7425:
Sigma).
Stable Cell Lines and Transient Gene Expression
Production of stable SpylA-HCll (pLXSN-Flag-Spyl-HCll) and Cntl-HCll
(pLXSN-HCll) cell lines was previously described (Golipour et al. 2008). Four
individual SpylA-HCll colonies were selected for use in this study, including two
individually infected mixed populations (Mixed population #1 and Mixed population #2)
as well as two separate colonies (Colony #3 and Colony #6). Stable colonies were
maintained in HC11 growth media supplemented with 400 uL/mL G418 (Sigma).
Transient transfections of HEK 293 and MDA-MB-231 cells were performed at
70 to 80% confluence, using 3 uL of 1 mg/mL of 25-kDa branched polyethylenimine
(PEI; 408727, Sigma) per 1 ng of DNA. PEI and DNA were vortexed with 5uL of 150
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mM NaCl per 1 ug of DNA and incubated for 10 minutes in separate tubes. After
incubation, the two tubes were combined, vortexed, and incubated for an additional 10
minutes, then applied drop-wise to the cells. Total protein was extracted 24-36 hours
post-transfection.
Immunoblotting and Immunoprecipitation
A previously published protocol for whole cell extract from mammary glands was
used to extract total protein from flash frozen mammary gland tissue (Zahnow et al.
1997). Total protein from cells in culture was obtained by subjecting cells adherent to
tissue plates to 0.1% NP40 lysis buffer (5 mL 10% NP40, 5 mL 0.5 mol/L EDTA, 10 mL
5 mol/L NaCl, 10 mL 1 mol/L Tris (pH 7.5), brought up to 500 mL reverse osmosis
water) supplemented with protease inhibitors (3 uL/mL of 20 mg/mL aprotinin, 10
uL/mL of 10 mg/mL phenylmethylsulfonyl fluoride, 10 uL/mL of 1 mg/mL leupeptin),
for 30 minutes on ice. Cells and lysis buffer were then collected into tubes, incubated on
ice for an additional 30 minutes, clarified by centrifugation at 10,000 rpm for 10 minutes
at 4°C. Protein concentrations were then determined via Bradford assay according to the
manufacturer's protocol (Sigma). Equal amounts of protein lysate per sample were
prepared (20-40 ug/sample of protein lysate from cells and 80-250 ug/sample of protein
lysate from tissue). For immunoprecipitation, lysates (500ug of 1 mg/mL protein) were
incubated with 1 ug of antibody overnight at 4°C. Protein G-Sepharose beads were then
added for 3 hours at 4°C. Samples were then centrifuged at 4°C at 5,500 rpm for 5
minutes, then washed 3 times with 600 mL 0.1% NP40 lysis buffer. Samples were boiled
for 5 minutes in 4* sample buffer, then ran on a denaturing 10% SDS-PAGE
(polyacrylamide gel) and subjected to electrophoresis at a 100V Gels were then
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transferred at 30V for 2.5 hours via a wet transfer system to a PVDF-PLUS transfer
membrane (Osmonics Inc.). Membranes were then blocked at room temperature for 1
hour in TBS-Tween 20 (TBST) containing 2.5% nonfat dry milk (blocker). Primary
antibodies were reconstituted in blocker at dilutions concurrent with individual
manufacturer's suggestions and incubated at 4°C overnight. Membranes were washed in
TBST three times, each for 15 minutes. Appropriate secondary antibody (anti-mouse IgG
[A9917; Sigma] or anti-rabbit IgG [A0545; Sigma]) was diluted in 1:10,000 blocker and
applied to membranes at room temperature for 1 hour. Membranes were then washed in
TBST

three

times,

chemiluminescent

each

peroxidase

for

10

minutes.

substrate-3

Immediately

(Sigma)

was

following

utilized

washes,

according

to

manufacturer's suggestions. Images were then quantified using AlphaEase FC software
on an Alpha Innotech HD2 (Fisher).
Mammary Gland Assays
The mammary gland developmental time course utilized the C57BL/6 mice strain.
Mammary glands were dissected from female C57BL/6 mice over a developmental time
course which included virgin, pregnancy, lactation and involution stages. Glands were
immediately flash frozen for protein extraction to be used in western blotting. C57BL/6
mice colonies were maintained according to the Association for Assessment of
Laboratory Animal Care guidelines and the assay was performed consistent with protocol
#1422 of the University of Tennessee Health Science Center.
The mammary fat pad transplant assays utilized the BALB/c mouse strain, which
is syngenic for the HC11 cell line. BALB/c mice colonies were maintained according to
the Canadian Council on Animal Care guidelines and assays were performed consistent
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with protocol #06-19 of the University of Windsor. Fat pad transplants were carried out
when virgin female BALB/c mice were between 21 and 23 days old. Proliferating HC11
stable colonies were grown in culture and re-suspended in lxPBS, where 5*105 cells of
either SpylA-HCl 1 or Cntl-HCl 1 were injected into the cleared right and left 4th inguinal
mammary gland, respectively. Subsequent surgeries to determine Wildtype-HCll
influence on mammary growth involved the substitution of Wildtype-HCl 1 for Spyl AHC11 cells in the cleared right gland. Post-transplanted mice were then housed
individually in separate cages and allowed to continue growth, monitored for tumor
incidence by weekly mammary palpitation beginning at 4 weeks post-surgery. SpylAHCl 1 and Cntl-HCl 1 glands were dissected from transplanted mice at the first detection
of rumor formation. Glands were then either flash frozen for genomic DNA extraction
and analysis or fixed in 10% neutral buffered formalin for immunohistochemistry.
Immunohistochemistry
Dissected glands fixed in 10% neutral buffered formalin were paraffin embedded
and sectioned via microtome (6 um/section). Sections were stained with Mayer's
hematoxylin and eosin P-phyloxine (Sigma) as previously described (Lenferink et al.
2000). Staining with PCNA antibody was conducted according to manufacturer's
suggestions.
Genomic PCR
Genomic DNA was extracted from 10 week post-surgery mammary glands (four
colonies of SpylA-HCl 1 and Cntl-HCl 1) using a PureLink Genomic DNA purification
kit according to the manufacturer's instructions (Invitrogen). Taq polymerase (New
England Biolab) was used in the PCR reaction, in addition to the following primers for
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human Spyl, which span an exon-exon junction and give an amplicon size of 130 base
pairs: Spyl A forward primer (A091) CCATGGGCTTTAGGGAAAAAC and Spyl A
reverse primer (A073) TGGCCATAACCTCCTCACAAC. Primers designed against the
flanks of the multicloning site of the empty pLXSN vector were also used, which give an
amplicon

size

of

117

base

CCCTTGAACCTCCTCGTTCGACC

pairs:

pLXSN

forward

primer

(A064)

and

pLXSN

reverse

primer

(A065)

GAGCCTGGGGACTTTCCACACCC. PCR conditions were optimized and included 30
cycles, 55°C annealing temperature and 2 minute extension time. PCR products were
subjected to an 8% polyacrylamide gel electrophoresis and were then treated with
ethidium bromide staining and visualized using GeneSnap (Syngene) software on a
Chemi Genius Bio Imaging System (Syngene).
Cell Motility Assays
To utilize the standard wound healing assay, cells were grown in monolayer on
cell counting grid cover slips (CELLocate coverslips; Eppendorf) in their specific culture
media until 100% confluence. Media was then aspirated, cells were washed with 1 x PBS
and a yellow pipette tip was used to wound the cells across the grid. 1 x PBS was then
aspirated and replaced with normal growth media. Cells were placed in normal growth
conditions and wound healing was monitored visually over a time course using Scope
2.0.4 Software.
Migration activity was investigated using a CytoSelect 24-well Cell Migration
Assay, 8 urn, Colorimetric Format, according to manufacturer's suggestion (CBA-100;
Cell Biolabs, Inc.). Specifically, cells were resuspended to a concentration of 0.5><106
cells/mL in serum free media, 10% fetal bovine serum (Sigma) was used as a
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chemoattractant and cells were incubated for 24 hours. Data was visualized using Scope
2.0.4 Software and quantified using the Victor3 1420 Multi-Label Counter (Perkin
Elmer) with a 590nm wavelength filter set.
Invasion activity was investigated using a CytoSelect 24-well Cell Invasion
Assay, 8 um, Colorimetric Format, according to manufacturer's suggestion (CBA-110;
Cell Biolabs, Inc.). Specifically, cells were resuspended to a concentration of 0.75x106
cells/mL in serum free media, 10% fetal bovine serum (Sigma) was used as a
chemoattractant and cells were incubated for 24 hours. Data was visualized using Scope
2.0.4 Software and quantified using the Victor3 1420 Multi-Label Counter (Perkin
Elmer) with a 590nm wavelength filter set.
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CHAPTER III
ANALYSIS OF RESULTS
SpylA protein is regulated during mammary gland development
To determine the protein levels of SpylA during mammary gland development,
C57BL/6 female mice were harvested across a developmental time course.
Immunoblotting of protein lysate obtained from homogenized mammary glands at
various time points demonstrates that SpylA is tightly regulated during development
(Figure 1). SpylA protein levels are high in the virgin gland and show an increase during
early pregnancy, where both stages are representative of times of high cell proliferation.
Levels of SpylA protein are then shown to decrease during times of differentiation,
which include late pregnancy and lactation. It is also interesting to note that SpylA
protein levels are high during involution of the gland 4 days post weaning, a phase of
high apoptosis. It can therefore be concluded that SpylA protein levels are upregulated
during periods of mammary gland proliferation and apoptosis and downregulated during
periods of differentiation.
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Figure 1. SpylA protein is regulated during mammary gland development.
C57BL/6 female mice mammary glands were harvested over a developmental
time course. Time points of study included: mature 12 week old virgin (Virgin), 6, 10, 15
days into pregnancy (6 Preg., 10 Preg., 15 Preg.), 10 days into lactation (Lactation) and 4
days forced involution (Involution). The mammary glands were homogenized, followed
by protein extraction. Protein lysates were analyzed on a 10% SDS-PAGE and
subsequently immunoblotted with SpylA antibody (upper panel). To confirm equal
protein loading between lanes, lysate concentration was determined via Bradford protein
assay and Actin antibody was probed onto the same blot (lower panel).
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Figure 1. SpylA protein is regulated during mammary gland development.

Genomic SpylA DNA is present in transplanted mammary glands.
To investigate the effects of SpylA on mammary gland development, the
mammary fat pad transplant system was utilized. Virgin pre-pubertal inguinal mammary
glands are cleared from their terminal end buds and the remaining fat pad is used to inject
cells, which reconstitute the gland as it develops. SpylA-HCll (from four individual
colonies including Mixed population #1, Mixed population #2, Colony #3, Colony #6)
and Cntl-HCl 1 stable cell colonies (0.5 x 106 cells) were injected into the cleared fourth
inguinal mammary gland of 21 day old virgin BALB/c female mice. To ensure that
Spyl A-pLXSN and empty pLXSN control were successfully integrated into transplanted
mammary fat pads, genomic DNA was extracted and purified 10 weeks post-surgery,
from both control pLXSN and the four SpylA-pLXSN colonies used (Mixed pop #1,
Mixed pop #2, Colony #3, Colony #6). PCR was performed to detect successful
integration of SpylA-pLXSN and pLXSN empty vector control, using primers designed
against an exon-exon boundary of SpylA (amplicon of 130 base pairs) or primers
designed against either side of the multicloning site of the pLXSN vector (amplicon of
117 base pairs), respectively (Figure 2). PCR with SpylA show bands at approximately
130 base pairs for all four SpylA-pLXSN colonies with no band present in the pLXSN
lane (Figure 2; top panel). When pLXSN primers were used, a band at approximately 117
base pairs was only present in the pLXSN control lane (Figure 2; bottom panel). These
results indicate that the mammary fat pad transplant system using Spyl A-HC11 or CntlHCl 1 stable colonies is an efficient method of expressing DNA in the mammary gland.
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Figure 2. Genomic Spy J A DNA is present in transplanted mammary glands.
Genomic DNA was isolated from transplanted mammary glands 10 weeks postsurgery. PCR analysis was performed on control HCll-pLXSN (pLXSN) and SpylAoverexpressing glands from all HCll-SpylA colonies utilized (SpylA-pLXSN; Mixed
pop#l, Mixed pop#2, Colony#3, Colony#6). In the top panel, primers designed against a
SpylA exon-exon boundary were used to amplify SpylA (130-bp amplicon size). The
bottom panel displays amplification of the empty pLXSN vector, with primers designed
against either side of the vector's multicloning site (117-bp amplicon size).
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Figure 2. Genomic Spy!A DNA is present in transplanted mammary glands.
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SpylA increases mammary gland proliferation in vivo.
To determine the effects of successful ectopic expression of SpylA on mammary
gland development, mammary fat pad transplants were performed using SpylA-HCll
(from four individual colonies including Mixed population #1, Mixed population #2,
Colony #3, Colony #6) and Cntl-HCll stable cell colonies (0.5 x 106 cells). Cells were
injected into the cleared fourth inguinal mammary gland of 21 day old virgin BALB/c
female mice and ten weeks post-surgery, transplanted glands were dissected from the
mice, followed by paraffin embedding, sectioning, and staining for PCNA (proliferating
cell nuclear antigen) and hematoxylin (Figure 3). An increase in PCNA staining in the
SpylA-HCll vs. Cntl-HCll glands demonstrates that overexpression of SpylA causes
an increase in cell proliferation (Figure 3A). PCNA-positive cells were counted over 3
different fields of view, with 200 cells per view, for Cntl-HC 11 (light grey column) and
SpylA-HCll (dark grey column) from three different samples (from Colony #3 and
Colony #6). Through quantification, a 6-fold increase in positive PCNA-staining of the
SpylA-HCll vs. Cntl-HCll glands was determined (Figure 3B). Overall, this data
demonstrates SpylA-HCll overexpressing mammary glands experience greater rates of
proliferation vs. Cntl-HC 11 transplanted glands.
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Figure 3. SpylA increases mammary gland proliferation in vivo.
10 weeks post-surgery, Cntl-HCll and SpylA-HCll transplanted mammary
glands were dissected, paraffin embedded, sectioned and stained for PCNA and
hematoxylin. (A) Representative serial sections at 63x magnification, from Cntl-HCll
{left) and SpylA-HCll Colony #3 {right), showing positive PCNA stain in brown,
hematoxylin back-stain in purple. (B) Quantification of the staining was obtained for both
Cntl-HCll and SpylA-HCll by counting positive PCNA stained cells over 3 different
fields of view. Each field of view contained 200 cells and SpylA-HCl 1 samples included
Colony #3 and Colony #6. The percentage of positive-PCNA stain is shown on the y-axis,
with bars on the x-axis representing Cntl-HCll {light grey column) and SpylA-HCll
{dark grey column). Error bars represent the standard error (SE) over 3 fields of view
from 3 separate samples for each Cnt-HCl 1 and SpylA-HCl 1.
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Figure 3. SpylA increases mammary gland proliferation in vivo.
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SpylA causes aberrant growth in vivo.
To further investigate the influence of Sp\ 1A s precocious growth effects in vivo
and the possibility that SpylA may stimulate tumori genesis, transplanted mice were
observed over time. Palpitation of both Sp\lA-HCll and Cntl-HCll glands was
conducted once a week. By 13 weeks post-surgery. 83% of the SpylA-HCl 1 transplanted
mammary glands, representing all four indhidual SpylA colonies, had large and easily
detectable tumors (Figure 4A, n=24). The contralateral Cntl-HCl 1 glands did not display
any tumor formation and all but one of the Sp\ 1A-HC11 glands was compararh ely larger
in size. The only Cntl-HCll injected fat pad that was larger than its complimentary
SpylA-HCl 1 gland did not have a palpable outgrowth or any solid tumor mass. The
SpylA-HCl 1 glands, howe\ er. de\ eloped solid tumors, with mam of them invading into
the fifth mammary gland or the stomach lining. Paraffin embedding and serial sectioning
of six SpylA-HCl 1 tumors and their Cntl-HCll glands, followed by hematoxylin and
eosin staining, demonstrated two distinct histological phenotypes. Four tumors displayed
very limited basophilic cytoplasm with large and pleomorphic nuclei and \esicular
chromatin. These tumors also grew either in diffuse sheets or sporadic glandular patterns
(Figure 4B). The last two tumors had copious eosinophilic cytoplasm with small and
ovoid nuclei and dense chromatin. When SpylA-HCl 1 and Cntl-HCll serial sections
were stained with PCNA, a 3-fold increase in positive PCNA-staining was observed in
SpylA-HCl 1 expressing tumors (Figure 4C and 4D). Overall, these results pro\ ide novel
and exciting data that suggest SpylA is capable of accelerating tumori genesis in the
mammary gland.
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Figure 4. SpylA causes aberrant growth in vivo.
Spyl-HCll (colonies Mixed Pop 1, Mixed Pop 2, Col 3, Col 6) and Cnt-HCll
transplanted BALB/c female mice were observed over time for aberrant mammary
development. (A) Tumor incidence is graphed, where SpylA-HCll Mixed Pop 1 (•).
Mixed Pop 2 (•), Col 3 ( A ) and Col 6 (•) overexpressing glands are represented with a
solid symbol and Cntl-HCll glands from the corresponding mice are represented with
hollow symbols. Transplanted mice were palpitated once every week post-surgery,
datapoints reflect the first onset of a palpitable tumor. The v-axis displays the percentage
of mice from the four transplanted populations that remain tumor-free, with the jc-axis
representing the number of weeks post-transplant. (B) At 16 weeks post-surgery, SpylAHC11 and contralateral Cntl-HCll glands were dissected, paraffin embedded, sectioned
and stained for hematoxylin and eosin. Representative serial sections are shown at 20 x
magnification (top) and 63x magnification
population 2 (left) and Cntl-HCll (right).

(C)

(bottom),

from

SpylA-HCll

Mixed

Serial sections were also stained for

PCNA and hematoxylin. Representative sections are shown at 63 x magnification (top),
with positive PCNA stain in brown, hematoxylin back-stain in purple, for Spyl A-HC11
(left) and Cntl-HCll (right). (D) Quantification of the staining was obtained for both
Cntl-HCll and SpylA-HCll by counting positive PCNA stained cells over 3 different
fields of view (bottom). Each field of view contained 200 cells per view and SpylAHC11 samples included Colony #3 and Colony #6. The percentage of positive-PCNA
stain is shown on the >>-axis, with bars on the x-axis representing Cntl-HCl 1 (light grey
column) and SpylA-HCll (dark grey column). Error bars represent the standard error
(SE) over 3 fields of view from 4 separate samples for each Cnt-HCl 1 and SpylA-HCl 1.
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Figure 4. Spyl A causes aberrant growth in vivo.
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Spontaneous tumorigenesis in the HCll model system in vivo.
Through the utilization of the mammary fat pad transplant system, it is clear that
SpylA-HCll injected glands undergo aberrant growth in comparison to those glands
injected with Cntl-HCll. It is, however, important to note that HCll cells have two
mutated p53 alleles, which contribute toward their immortalized phenotype. To
investigate if Wildtype-HCl 1 cells had any growth effects in vivo, they were also injected
into the cleared fat pads of 21 day old female BALB/c mice and observed over time for
any signs of palpitable tumor formation. It was shown that the majority of SpylA-HCl 1
glands developed tumors before 14 weeks post-transplant (Figure 4A). Wildtype-HCl 1
and contralateral Cntl-HCll injected glands showed no palpitable signs of tumor
formation at 14 weeks post-transplant, but were allowed to develop further over time. A
small percentage (16.7%) of both Wildtype-HCl 1 and Cntl-HCll injected glands
developed palpitable outgrowths by 20 weeks post-surgery. All Wildtype-HC 11 injected
glands had tumor formation by 28 weeks post-surgery, with only 16.7% of the CntlHCll glands remaining tumor free. The tumor formation of the Wildtype-HC 11 and
Cntl-HCll transplanted mammary glands developed at a much slower rate than SpylAHC11 glands (Figure 5). These results indicate that HCll cells do have the ability to
cause tumor formation over time; SpylA overexpression greatly accelerates any aberrant
growth and consequential tumor formation.
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Figure 5. Spontaneous tumorigenesis in the HC11 model system in vivo.
Mammary fat pad transplants were performed in virgin 21 day old female
BALB/c mice using Wildtype-HCl 1 and Cntl-HCl 1 cells (n=6). Transplanted mice were
then observed over time for palpitable mammary gland tumor formation. Tumor
incidence is graphed, where Wildtype-HCll (•) and Control-HCll (A) overexpressing
glands are graphed in addition to an average of tumor incidence from the SpylA-HCl 1
(•) transplanted mice previously depicted in Figure 4A (n=24). Transplanted mice were
palpitated once every week post-surgery, with the graph depicting the first onset of a
palpitable tumor. The y-axis displays the percentage of Wildtype-HCll and Cntl-HCl 1
mice that remain tumor-free compared with the average of Spyl A-HC11 mice. The xaxis represents the number of weeks post-transplant.
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Figure 5. Spontaneous tumorigenesis in the HCll model system in vivo.
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SpylA endogenous protein expression varies in different cell lines.
To investigate the presence of endogenous SpylA in various breast cell lines,
immunoblotting was performed from total protein lysate from an array of cultured cells.
Cells included HC11, BALB/C mouse mammary epithelial cell line, MCF 10A, nontumorigenic human breast epithelial cell line, MCF7, human mammary adenocarcinoma
epithelial

cell

line,

MDA-MB-231

and

MDA-MB-468,

human

mammary

adenocarcinoma epithelial cell lines. Immunoblotting these cell lysates with SpylA
antibody showed the presence of endogenous levels of SpylA in MCF-10A and MDAMB-231 cells but no SpylA was present in HCl 1, MCF7 or MDA-MB-468 cells (Figure
6). It is interesting to note that SpylA was present in a normal breast cells (MCF-10A) as
well as a highly invasive breast cancer cells (MDA-MB-231) and yet absent in human
mammary adenocarcinoma cells (MCF7) and modestly invasive breast cancer cells
(MDA-MB-468). These results may indicate that SpylA is present in normal human
breast epithelial cells, downregulated in non-metastatic breast cancers and overexpressed
in invasive breast cancers.
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Figure 6. SpylA endogenous protein expression varies in different cell lines.
HC11, MCF-10A, MCF7, MDA-MB-231 (231) and MDA-MB-468 (468) were
cultured in their respective growth media and total protein lysates were collected from
proliferating cells. Lysates were analyzed on a 10% SDS-PAGE and subsequently
immunoblotted with SpylA antibody (upper panel). To confirm equal protein loading
between lanes, lysate concentration was determined via Bradford protein assay and
confirmed by probing Actin antibody onto the same blot (lower panel).
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Figure 6. SpylA endogenous protein expression varies in different cell lines.
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SpylA endogenous protein is present in human breast metastases.
To determine the possibility of endogenous SpylA protein being present in
metastasized breast cancers, brain tumor tissues metastasized from primary breast tumors
were homogenized and total protein was extracted. Immunoblotting of these protein
lysates shows that endogenous SpylA is present in 43% of brain metastasized tumor
tissues with no detectable SpylA in normal mouse liver (Figure 7). This data implies that
endogenous SpylA levels can be found in brain cancers that have metastasized from
primary breast tumors.
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Figure 7. SpylA endogenous protein is present in human breast metastases.
Seven individual human female brain cancers metastasized from primary breast
tumors were provided as flash frozen samples from the Ontario Brain Bank (Brain Met:
1025, 908, 902, 875, 859, 848, 485). The tumor samples as well as a normal mouse liver
as control were then homogenized, followed by protein extraction. Protein lysates were
analyzed on a 10% SDS-PAGE and then immunoblotted with SpylA antibody (upper
panel). To confirm equal protein loading between lanes, lysate concentration was
determined via Bradford protein assay and Actin antibody was probed onto the same blot
(lower panel).

52

Figure 7. SpylA endogenous protein is present in human breast metastases.
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SpylA overexpression increases cells ability to heal a wound.
Previous results in this thesis demonstrate that ectopic SpylA causes accelerated
mammary gland proliferation in vivo, consequently leading to tumorigenesis (Figures 3
and 4). This research has also shown that endogenous SpylA protein levels can be found
in both a normal breast (MCF-10A) and an invasive breast cancer (231) cell line as well
as in brain tumors metastasized from the breast (Figures 6 and 7). This evidence leads to
the hypothesis that SpylA could be playing a role in cell migration and/or invasion. To
determine the effects of SpylA on cell proliferation and potential migratory effects, a
wound healing assay was performed in HC11 cells (Figure 8). By monitoring Cntl-HCl 1
and SpylA-HCl 1 cells grown in monolayer and wounded with a pipette tip over time, it
was visually evident that cells overexpressing SpylA increased the rate at which the cells
closed the wounded space (Figure 8A). Measuring the distance the cells traveled
quantifies this observation, showing that SpylA overexpression in HC11 cells stimulates
a more rapid rate of wound closer compared to Cntl-HCl 1 (Figure 8B). This data
demonstrates that SpylA stimulates proliferation in HC11 cells.
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Figure 8. Spy!A overexpression increases cells ability to heal a wound.
A wound healing assay was performed using either SpylA-HCll (Mixed
population #1) or Cntl-HCl 1 cells. The cells were grown in their normal growth media
on top of gridded cover slips. Once 100% confluence was reached, the cell monolayer
was scraped across the gridded area. (A) Wound closure was monitored visually over
time at time points 0 hr, 3.5 hr, 6 hr, and 17 hr, with Cntl-HCl 1 in the left panels and
SpylA-HCll in the right panels (B) Distance traveled was quantified by counting
number of grid squares closed by the cell front, which is depicted graphically where CntlHCl 1 are represented by (A) and SpylA-HCll are represented by (•). The .\-axis
represents the time in hours post-wound and the v-axis displays the distance traveled, as
measured by grid spaces. Error bars represent the standard error (SE) over 3 trials.
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Figure 8. SpylA overexpression increases cells ability to heal a wound.
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SpylA overexpression can decrease the rate of cell migration.
Spyl A's influence on migration was further investigated through utilization of the
Cyto-Select Migration Assay, in both HCll and 231 cell lines (Figure 9). This assay
utilizes a Boyden chamber method where cells plated in serum starved media in an upper
chamber can migrate towards a chemoattractant through a polycarbonate membrane to a
lower chamber, indicating migratory capabilities. Stably expressing SpylA-HCll and
Cntl-HCl 1 cells were utilized, showing the SpylA overexpression decreased the rate of
cell migration (Figure 9A). Similarly, transient expression of SpylA in 231 cells
decreased rates of migration in comparison to Cntl cells (Figure 9B). These data
demonstrate SpylA overexpression can decrease the rate of cell migration.
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Figure 9. Spy! A overexpression can decrease the rate of cell migration.
(A) Stably expressing Spyl A-HC11 and Cntl-HCl 1 cells were used in the CytoSelect Migration Assay (Figure 9A). After 24 hours of incubation, cells were stained and
visualized under the microscope, where purple staining represents cells that have
migrated through the polycarbonate membrane (Figure 9A; upper panel). The migrated
and stained cells were then extracted from the membrane and quantified via absorbance
reading at 590 nra. Results are depicted graphically, where the y-axis represents the OD
value at 590 nm and the x-axis displays the incubation time in hours (Figure 9A; lower
panel). Error bars represent the standard error (SE) over 3 trials, with p-value set for
significance at 0.05. (B) 231 cells were transfected with either Spyl A (pCS3-MycSpylA) or Cntl (pCS3-Myc) (Figure 9B; upper panel). Transiently expressing SpylA231 and Cntl-231 cells were used in the Cyto-Select Migration Assay (Figure 9B; middle
and lower panels). After 24 hours of incubation, cells were stained and visualized under
the microscope, where purple staining represents cells that have migrated through the
polycarbonate membrane (Figure 9B; middle panel). The migrated and stained cells were
then extracted from the membrane and quantified via absorbance reading at 590 nm.
Results are depicted graphically, where the y-axis represents the OD value at 590 nm and
the x-axis displays the incubation time in hours (Figure 9B; lower panel). Error bars
represent the standard error (SE) over 3 trials, with p-value set for significance at 0.05.
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Figure 9. SpylA overexpression can decrease the rate of cell migration.
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siRNA-mediated knockdown of SpylA can increase the rate of cell migration.
To further study the effects of SpylA on migration, either siRNA-SpylA or
siRNA-Cntl transfected 231s were used in the Cyto-Select Migration Assay to assess the
influence of cell migration rates when SpylA levels are decreased (Figure 10). Transient
transfections were performed in 231s using either siRNA-Spyl or siRNA-Cntl (Figure
10A). This assay demonstrates that siRNA-mediated knockdown of SpylA can
significantly increase migration rates in comparison to control (Figure 10B and IOC).
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Figure 10. siRNA-mediated knockdown of Spy 1A can increase the rate of cell migration.
Transiently expressing siRNA-SpylA or siRNA-Cntl 231 cells were used in the
Cyto-Select Migration Assay (Figure 10). (A) Denso-spot analysis was conducted to
confirm SpylA knockdown in 3 separate transfected populations (siSpyl), where SpylA
relative units are represented on the y-axis. (B) After 24 hours of incubation, cells were
stained and visualized under the microscope, where purple staining represents cells that
have migrated through the polycarbonate membrane. The migrated and stained cells were
then extracted from the membrane and quantified via absorbance reading at 590 nm. (C)
Results are depicted graphically, where the y-axis represents the OD value at 590 nm and
the x-axis displays the incubation time in hours.
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Figure 10. siRNA-mediated knockdown of Spyl A can increase the rate of cell migration.
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SpylA overexpression does not influence the rate of cell invasion.
Due to interesting results showing SpylA's ability to increase the rate of wound
healing, which could indicate an increase in cellular proliferation and/or an increase in
migration, and SpylA's influence on decreasing migration in a migration assay (Figures
8 and 9, respectively), the effects of SpylA on cellular invasion were investigated. The
Cyto-Select Invasion Assay was utilized with 231 cell lines (Figure 11). Similar to the
Migration Assay, this Boyden chamber method plates cells in serum starved media in an
upper chamber, and those cells expressing invasive properties can invade towards a
chemoattractant through a mock basement membrane to a lower chamber. Transient
expression of SpylA in 231 cells showed that overexpression of SpylA did not influence
the rate of invasion (Figure 11 A). Similarly, transient siRNA mediated knockdown of
SpylA did not influence the rate of invasion (Figure 1 IB). These data indicate that
SpylA does not play a role in invasion in the 231 cell line.
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Figure 11. SpylA overexpression does not influence the rate of cell invasion.
(A) Transiently expressing SpylA-231 and Cntl-231 cells (as used in Figure 9B;
upper panel) were used in the Cyto-Select Invasion Assay (Figure 11A). After 24 hours
of incubation, cells were stained and visualized under the microscope, where purple
staining represents cells that have invaded through the mock basement membrane (Figure
11 A; upper panel). The invasive and stained cells were then extracted from the membrane
and quantified via absorbance reading at 590 nm. Results are depicted graphically, where
the x-axis represents the OD value at 590 nm and the y-axis displays the incubation time
in hours (Figure 11A; lower panel). Error bars represent the standard error (SE) over 3
trials, with p-value set for significance at 0.05. (B) Transiently expressing siRNA-SpylA
or siRNA-Cntl 231 cells were used in the Cyto-Select Invasion Assay (Figure 11B). After
24 hours of incubation, cells were stained and visualized under the microscope, where
purple staining represents cells that have invaded through the mock basement membrane
(Figure 1 IB; upper panel). The invasive and stained cells were then extracted from the
membrane and quantified via absorbance reading at 590 nm. Results are depicted
graphically, where the y-axis represents the OD value at 590 nm and the x-axis displays
the incubation time in hours (Figure 1 IB; lower panel). Error bars represent the standard
error (SE) over 3 trials, with p-value set for significance at 0.05.
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Figure 11. SpylA overexpression does not influence the rate of cell invasion.
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SpylA interacts with Axin.
A yeast-two hybrid hit showed a potential protein-protein interaction between
SpylA and Axin, a key player in the Wnt signal transduction pathway, which is known to
play roles in mammary development and carcinogenesis (data not shown). To confirm
this interaction, HEK293 cells were transfected with either pCS3-Myc, pCS3-MycSpyl A, or pCS2+-Flag-Axin (Figure 12A). Protein lysates were immunoprecipitated with
Axin antibody to detect Spyl A-Axin binding (Figure 12B) and IgG antibody as a control
to confirm equal IgG bead loading between samples (Figure 12C). Immunoblotting of
Axin immunoprecipitates shows a protein interaction between overexpressed Myc-Spyl A
(Figure 12B; lower panel). These results imply that SpylA may be playing a role in the
Wnt signal transduction pathway through its interaction with one of the pathway's key
proteins, Axin.
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Figure 12. SpylA interacts with Axin.
HEK 293 cells were transfected with control pCS3-Myc, pCS3-Myc-Spyl or
pCS2+-Flag-Axin. Total protein was extracted 36 hours post-transfection and lysate was
resolved on a 10% SDS-PAGE and transferred to a membrane. The membrane was then
immunoblotted with Flag and Myc antibodies to confirm Axin and Spyl overexpression,
respectively, as well as with Axin antibody to detect endogenous Axin (Figure 12A; top
three panels). Equal protein loading was verified by determining lysate concentration via
Bradford assay as well as probing for Actin on the same blot (Figure 12A; bottom panel).
Cell lysates were subsequently immunoprecipitated with Axin antibody and separately
with IgG antibody as a control. Immunoprecipitate samples were then analyzed by 10%
SDS-PAGE and transferred to a membrane. Axin immunoprecipitates were probed with
Axin antibody to detect total Axin (Figure 12B; top panel). It was also probed with Myc
antibody to detect overexpressed Myc-SpylA protein binding to Axin (Figure 12B;
bottom panel). IgG immunoprecipitates were probed with IgG antibody as a control to
confirm equal IgG bead loading between samples (Figure IOC; upper panel), as well as
with SpylA antibody to ensure binding observed in the Axin immunoprecipitates with
SpylA was specific (Figure 12C; lower panel).
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Figure 12. Spy IA interacts with Axin.
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CHAPTER IV
DISCUSSION AND CONCLUSIONS
In humans, breast cancer is the most common cancer among women. One in 9
women will be diagnosed with breast cancer in their lifetime and 1 in 27 women will die
because of it (CCS/NCIC 2007). These devastating statistics highlight the importance of
research efforts to unveil cellular mechanisms that can lead to mammary tumorigenesis.
The study of mammary gland development provides a comprehensive framework for the
investigation of regulated cellular decisions during significant processes such as growth,
proliferation,

differentiation,

migration, invasion and apoptosis. Comprehensive

knowledge of these tightly regulated signaling mechanisms may provide better
understanding of normal development, as well as insight into any number of cellular
events involved in the initiation and progression of abrogated growth, such as
tumorigenesis.
A recent SAGE analysis disclosed SpylA as one of the 50 most up-regulated
genes in invasive ductal carcinoma of the breast (Zucchi et al. 2004). Furthermore, results
within this thesis have demonstrated that SpylA protein levels are tightly regulated
during a developmental time course in C57BL/6 mice (Figure 1). High levels of
endogenous SpylA protein are present in the proliferating virgin mammary gland and
these levels remain high in early stages of pregnancy, which is also a time of mammary
gland growth. SpylA protein levels decrease significantly by late pregnancy and during
lactation, indicative of terminal differentiation in the gland. Yet, captivatingly, levels of
SpylA are also high in involution, a stage of rapid apoptosis of the gland following
weaning. It has also been shown that SpylA mRNA levels coincide with the protein
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expression pattern and immunohistological staining shows that SpylA is present in high
amounts in the epithelial cells of pregnant and involuting mammary glands, with little
expression evident in the myoepithelial cell stroma (Golipour et al. 2008). Collectively,
this data confirms that SpylA is tightly regulated during the development of the
mammary gland. This knowledge naturally leads to the hypothesis that abrogation of
normal SpylA levels may consequently cause abnormal mammary development.
To investigate this hypothesis, a cellular model was employed through the
utilization of the mammary epithelial cell line HC11 in vivo. This cell line is frequently
used in the study of growth and differentiation because these cells can differentiate
appropriately in response to prolactin and dexamethasone, lactation hormones (Doppler
et al. 1989). HC11 cells overexpressing SpylA have abrogated cellular morphology, and
display an absence of proper acini formation in cell culture (Golipour et al. 2008). In
addition to cell culture techniques, it is important to note that the HC11 cell line was
originally isolated from a female mid-pregnant BALB/c mouse, making it syngenic with
this mouse strain. This allows for the HC 11 cell line to be utilized in the standard cleared
mammary fat pad technique, employed by researchers to quickly and efficiently study the
effects of ectopic gene expression on mammary gland development and carcinogenesis.
Four separate HC11 colonies stably expressing SpylA (SpylA-HCll) in addition to an
HC11 pLXSN vector control cell colony (Cntl-HCl 1) were used in the mammary fat pad
system, and it was shown that SpylA and control pLXSN genomic DNA is present in the
mammary gland 10 weeks post transplant (Figure 2). As well, histological analysis by
PCNA stain shows that SpylA expression increases proliferation in the gland as early as
10 weeks post transplant (Figure 3). Whole mount analysis also demonstrates that SpylA
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overexpressing glands experience precocious lobular development, including an increase
in ductal side branching and TEB formation (Golipour et al. 2008).
When observed over a longer time period and monitored by weekly mammary
palpitation for tumor onset, it was shown that 83% of SpylA expressing glands displayed
large and easily detectable rumors, whereas the contralateral Cnt-HC 11 glands did not
display any tumor formation (Figure 4). Upon dissection, it was evident that these tumors
were invasive, many entering the stomach lining as well as reaching into the fifth
inguinal mammary gland. The SpylA tumors were solid and displayed an increase in
PCNA staining, indicating an increase in proliferation. Staining for cell type markers
showed that tumors had numerous positive keratin 8/18 cells, characteristic of luminal
epithelial cells and consequently displayed a low number of positive anti-smooth muscle
actin cells, which are indicative of myoepithelial cells (Golipour et al. 2008). When
examined histologically, the tumors appeared to demonstrate two distinct phenotypes
(Figure 4). SpylA tumors either displayed limited basophilic cytoplasm with large,
pleomorphic nuclei and vesicular chromatin, growing in diffuse sheets or sporadic
glandular patterns or they displayed copious eosinophilic cytoplasm with small and ovoid
nuclei with dense chromatin. This difference in tumor phenotype could be due to the
microenvironment the cells were first injected into in the fat pad, where various external
signals could operate via epithelial-mesenchymal signaling, uniquely influencing the
downstream effects on SpylA.
With the mammary fat pad studies, it is important to note that the HC11 cell line
is immortalized, meaning it grows incessantly in culture. Additionally, it has 2 mutant
p53 alleles, which make it more susceptible to aberrant growth potential. In order to
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determine if the HC 11 cells alone could cause tumorigenesis in vivo, mammary fat pad
transplants were performed using Wildtype-HCll

and Cntl-HCll. Long term

observation of these transplanted mice revealed that both Wildtype-HCl 1 and Cntl-HCl 1
cells caused aberrant growth leading to tumorigenesis. Whereas the majority of SpylAHC11 glands developed tumors before 14 weeks post-surgery, the tumors that formed in
Wildtype-HCll and Cntl-HCll transplanted glands occurred between 20 and 28 weeks
post-surgery (Figure 5). This evidence indicates that HC11 cells maintain the ability to
cause tumor formation over time, but it is also clear evidence that SpylA overexpression
greatly accelerates aberrant growth and subsequent tumor formation.
The question remains, does SpylA have the ability to initiate mammary
oncogenesis? This subject can be addressed via many in vivo approaches. Firstly,
utilization of primary mammary epithelial cell lines is the most direct methodology that
should be employed. Using the same BALB/c mice strain, primary epithelial cells can be
extracted from a virgin mammary gland and cultured for a short period of time. The cells
can then be exposed to viral transduction, where SpylA or Cntl can be integrated into the
cells via viral-mediation (Kordon & Smith 1998). The Porter Lab is now moving forward
with a lentiviral system, which will enable successful integration of SpylA into the
isolated primary cells. Once it has been confirmed that the lentiviral mediated integration
of SpylA into primary mammary epithelial cells is successful and SpylA is expressed,
transplant surgeries can be performed and the mice will be monitored for tumor
formation via the same techniques as the HCl 1 transplanted mice. If these mice develop
rumors, it will signify that SpylA is able to initiate tumor formation, seeing as the cells
will be free from any other mutation, thereby indicating abnormal growth effects are a
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sole result of ectopic Spyl A expression. It is also possible, and quite likely, that Spyl A is
mediating tumor formation through a "two-step" process, where if a cell has a previous
genetic mutation, the influence of Spyl A may act as a second "hit", spurring the cell into
uncontrolled growth and division leading to tumorigenesis (Knudson 1971). To test this
hypothesis, mice transplanted with primary cells stably expressing Spyl A will be
exposed to irradiation, which would act as the first genetic "hit" Mice would be
monitored over time, where any aberrant growth or tumor formation would be indication
that Spyl A is not solely capable of causing tumorigenesis, but rather acts in
corroboration with other genetic defects to influence aberrant growth.
This research also aimed to further investigate Spyl A" s role in cellular
proliferation, migration and invasion. Firstly, Spyl A protein levels were examined in cell
lines ranging from normal to cancerous to invasive breast epithelial cells. Investigation of
endogenous Spyl A levels in various breast epithelial cell lines showed Spyl A present in
high levels in MCF-10A, a non-tumorigenic human breast epithelial cell line and in
MDA-MB-231, a highly invasive human mammary adenocarcinoma epithelial cell line
(Figure 6). It was also shown that endogenous Spyl A levels can also be detected in
human breast tumors metastasized from breast (Figure 7). Taking this new information
into consideration with the recent finding that Spyl A is up-regulated in invasive ductal
carcinoma of the breast, it is logical to hypothesize that Spyl A is playing a role in tumor
cell invasion.
Wound healing assays of HC11 cells grown in monolayer, demonstrate that
overexpression of Spyl A increases a cells ability to heal a wound (Figure 8). Seemingly
contradictory to this finding, when Spyl A is overexpressed in MDA-MB-231 and HC11
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cells, the ectopic expression decreases their ability to migrate through a polycarbonate
chamber, in a Boyden chamber cellular migration assay (Figure 9). Similarly. siRNA
mediated knockdown of Spy 1A increases the rate of migration in the MDA-MB-231 cell
line (Figure 10). Upon initial observation, these results appear to be contradictory to each
other, as the wound healing assay is typically thought to be a good indication of the
migratory potential of a cell. While this is true, it also remains true that this assay
demonstrates a cells proliferation capabilities. Also, since cell monolayers are grown to
confluence before wounding, cells will have entered a quiescent Go phase, where
increased rate of wound healing could signify an increased ability to exit from Go back
into the cell cycle. Since the cellular migration assay indicates that SpylA decreases the
rate of migration, it is hypothesized that the increase in wound healing observed with
SpylA overexpression is due to an increase in proliferation, an increased ability to reenter the cell cycle, or a combined effect of the two processes. Interestingly, the
overexpression or siRNA mediated knockdown of SpylA in MDA-MB-231 cells does
not influence the rate of cellular invasion, as measured by a Boyden chamber cellular
invasion assay (Figure 11).
This medley of information demonstrates that the role of SpylA in processes of
proliferation, migration and invasion is not straightforward. Ultimately, future research is
needed to gather a more comprehensive knowledge of SpylA"s influence on these
effects. SpylA has been shown to interact in the MAPK. signaling pathway, and evidence
in this thesis indicates that it could also be playing a role in the Wnt signal transduction
pathway through its interaction with Axin (Figure 12). Axin is a known tumor
suppressor, based on its ability to form a degradation complex with other proteins to aid
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in the phosphorylation and down-regulation of |3-catenin. This has been confirmed by
evidence showing human hepatocarcinoma has biallehc inactivation of Axin (Satoh et al
2000). P-catenin is typically found in the cytoplasm in the absence of Wnt signaling,
where it can bind to E-cadhenn, playing a role in the structural organization of the actin
cytoskeleton (Takeichi 1991) E-cadhenn is important for cell-cell adhesion and its
degregulation is known to be a marker for transition of a cell phenotype from epithelial to
mesenchymal, a process that occurs dunng cell migration and is thought to be important
in tumor progression (Aberle et al 1996, Weinberg 2006) When Wnt signaling is active
P-catemn is not degraded and its accumulation in the cytoplasm causes it to enter the
nucleus, where it binds to the transcnption factor Tcf/Lef, stimulating expression of
genes such as c-Myc (Polakis 2000)
Many technical issues plagued further investigation into this interaction within the
realm of this thesis, but future research will be able to elucidate SpylA's role in Wnt
signaling The same yeast two hybnd that identified a potential protein-protein interaction
between SpylA and Axin also shows a hit for LRP6, indicating that SpylA may also
interact with LRP6, the transmembrane receptor of the Wnt signaling pathway Although
this was not confirmed, future expenments will elucidate SpylA s involvement with
LRP6 and its potential interactions with Axin Three dimensional models of cell growth
can also be utilized, where normal breast epithelial cells (MCF-10A) are grown on a
basement membrane, mimicking an in vivo microenvironment Localization of SpylA
and Wnt markers can then be studied, providing insight into the interaction of these
proteins. It would also be beneficial to study these interactions at an endogenous level,
without overexpression, which gives a clear indication of the true interaction between
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two proteins. In order to study Wnt and its effectors, many researchers utilize Xenopus
oocytes, and this method of study would provide a good future direction for this project.
Lastly, general hypotheses can be made from the evidence collected in this thesis
for SpylA's role in processes such as migration and invasion. An Axin transgenic mouse
model indicates that ectopic Axin expression causes abnormalities in mammary gland
development. Glands undergo normal ductal elongation and side branching but have
deficient lactation abilities and undergo increased apoptosis (Hsu et al. 2001). The
ectopic expression of Wnt in the mouse mammary tumor virus (MMTV)- Wnt I transgenic
mice results in faster ductal outgowth compared to controls, which leads to
lobuloalveolar hyperplasia and virgin transgenic mammary glands resemble wild-type
mammary glands in mid-pregnancy (Lane & Leder 1997; Lin et al. 1992). This is similar
to the SpylA tumor phenotype, indicating that SpylA may be eliciting its tumorigenic
effects through the Wnt signaling pathway. Accelerated development of the mammary
gland when transplanted with SpylA is similar to a p27 hemizygous knockout mouse.
Interestingly, p27 null mammary glands experience a reduction in ductal branching and
hypoplasia (Muraoka et al. 2001). As previously stated, SpylA has been shown to play a
role in enhancing the degradation of p27 (Porter et al. 2003). It has also been shown that
p27-deficient primary fibroblasts experience a failure to migrate (McAllister et al. 2003).
This may indicate one potential hypothesis for the observed decrease in cell migration
when SpylA was overexpressed (Figure 9).
It is also interesting to note that large, high grade, invasive rumors display a
decrease in E-cadherin (Suciu et al. 2008). Results in this thesis demonstrate that SpylA
was shown to be up-regulated endogenously in the MDA-MB-231 cell line, which is also
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known to have loss of E-cadherin (Figure 6). Wound healing data demonstrated that
SpylA overexpression increased the cell's ability to heal the wound, implicating that
SpylA may be increasing a cell's ability to exit from G0 to re-enter the cell cycle. This
ability would be very beneficial to a tumor cell migrating from its primary tumor mass. It
is known that the rate-limiting stage of metastasis is the colonization of the primary
tumor cell in its new microenvironment, and stimulation out of Go phase would increase a
cell's liability to survive in these conditions. This may further imply SpylA's correlation
with invasive breast cancer. It is also interesting that in the SAGE analysis identifying
SpylA as one of the 50 most up-regulated genes in invasive ductal carcinoma, SpylA
was not found to be up-regulated in metastatic ductal carcinoma, further supporting the
complex reality of SpylA's function in vivo (Zucchi et al. 2004).
It is important to realize that the cellular assays completed in the latter section of
this thesis provide evidence of SpylA's role in a various cell culture environments. The
migration assay demonstrates an environment void of upstream signaling, where no Wnt
signal is present. Comparatively, the wound healing assay triggers external signals, and
could represent the presence of a Wnt signal. Using this theory, the discrepancies in
results between assays could be due to SpylA's involvement in the Wnt pathway. In the
absence of a Wnt signal, SpylA could bind to Axin as part of the P-catenin degradation
complex, increasing recruitment of p-catenin to the complex and consequently increasing
its phosphorylation and degradation. Decrease in P-catenin levels would then result in
less translocation of cytoplasmic P-catenin into the nucleus, resulting in less transcription
of downsteam Wnt targets and a consequential decrease in migration, as seen in the
migration assay. In the presence of a Wnt signal, bound to LRP6 at the plasma
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membrane, theoretically Spyl could bind to Axin, causing translocation of the
degradation complex to LRP6 at the plasma membrane. This would inhibit the
degradation complex from phosphorylating P-catenin, resulting in an increase in cytosolic
P-catenin, which would amplify the amount of protein that could translocate to the
nucleus, causing downstream activation of Wnt target genes and an increase in migration,
as seen in the wound healing assay. Further investigation into the contribution of the
cellular microenvironment is required in order to make statements with regard to the
implications of these results on the in vivo physiology occurring in the normal and
abnormal mammary gland.
Collectively, the research within this thesis has demonstrated that Spyl A is tightly
regulated during mammary development and is present in high levels at stages of
proliferation, growth, and cellular apoptosis. Utilizing an in vivo mammary transplant
model, it was shown that ectopic expression of Spyl A can lead to precocious mammary
gland proliferation, in turn accelerating the onset of breast cell tumorigenesis. In cell
culture, overexpression of Spyl A was also shown to increase the rate of cell cellular
wound healing. Endogenous Spyl A protein has also been found in high levels in the
invasive human mammary adenocarcinoma epithelial cell line, MDA-MB-231, as well as
in some samples of human breast cancer metastasized to the brain. Yet, through
utilization of migration and invasion cellular assays, Spyl A overexpression appears to
decrease the rate of cell migration and play no immediately evident role in the rate of cell
invasion. This thesis has also revealed a novel protein-protein interaction between Spyl A
and Axin, a scaffolding protein known to play an important role in the Wnt signal
transduction pathway.
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This body of research has demonstrated that Spyl A is important for normal
mammary gland development and ectopic Spyl A expression accelerates mammary breast
cell tumori genesis. The mechanism by which Spyl A is acting in order to stimulate such
events is still unclear, but SpylA has previously been shown to be involved in the
regulation of proteins such as p27 and c-Myc, with evidence from this thesis indicating
that SpylA could be involved in the Wnt pathway through its interaction with Axin.
Future research, in part outlined in this discussion, will be required in order to investigate
the myriad of possible signaling mechanisms that could be influencing SpylA and its
involvement in breast cell tumorigenesis.
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